Veraxa Biotech is trading 6.25% down at $1.65, pressured by softer broader-market sentiment and likely profit-taking after a sharp multi-session rally.
- Shares have retreated from the September 4 close of $1.76.
- No new company-specific announcement was identified for September 8, 2026.
- The latest catalyst was the September 4 CFO appointment, which previously supported gains.